Regular Paper
Impact of immunoprophylaxis and patient selection on outcome of transplantation for HBsAg-positive liver recipients

https://doi.org/10.1016/S0168-8278(05)80396-4Get rights and content

We have studied the roles of immunoprophylaxis, patient selection policy and coexistent hepatitis D virus infection in the outcome of 56 HBsAg-positive elective liver transplant recipients. Twenty-nine unselected patients not treated with immunoprophylaxis formed group 1 and were compared to a recent consecutive series of 27 patients (group 2) in whom pre-transplant serological status was determined and who received immunoprophylaxis. One-year actuarial HBsAg serological recurrence rates were 48% in group 2 and 90% in group 1 with particular improvement in recipients who were either HBV DNA-negative or who had co-existent hepatitis delta virus infection. One-year patient survival has improved from 62% in group 1 to 86% in group 2 with improvements in hepatitis delta virus-negative and replicating recipients. Patients who have either co-existent hepatitis delta virus infection or are in group 2 have 1-year survival rates comparable to elective HBsAg-negative recipients (19/21 (90%), 22/27 (86%) vs 87%, respectively). In the event of recurrence, severe graft injury is diminished in recent patients and in those with coexistent delta infection who also have lower levels of circulating HBV DNA. Retransplantation for associated graft injury has a poor prognosis irrespective of administration of immunoprophylaxis. In elective liver recipients, immunoprophylaxis and/or hepatitis delta virus infection modulate hepatitis B virus recurrence and associated graft injury with consequent improvement in patient survival.

References (14)

There are more references available in the full text version of this article.

Cited by (51)

  • Immunomodulation by hyperimmunoglobulins after solid organ transplantation: Beyond prevention of viral infection

    2017, Transplantation Reviews
    Citation Excerpt :

    In the beginning of the 1990’s two seminal studies by Samuel et al. demonstrated that the recurrence of HBV after LTx could be significantly reduced by high dose HBIg therapy [74,75]. Administration of 10,000 international units (IU) HBIg intra-operatively during the anhepatic phase, daily infusions of 10,000 IU HBIg during the first post-transplant week, followed by 10,000 IU per month thereafter, decreased recurrence rates to 20%–40%, resulting in improved survival rates, comparable with those of non-HBV LTx recipients [74–77]. However, HBIg monotherapy could not prevent HBV-recurrence in most patients with high viral load at the time of LTx.

  • Prevention of recurrent hepatitis B infection after liver transplantation

    2013, Hepatobiliary and Pancreatic Diseases International
  • Does pre-liver transplant HBV DNA level affect HBV recurrence or survival in liver transplant recipients receiving HBIG and Nucleoside Analogues?

    2011, Annals of Hepatology
    Citation Excerpt :

    The only patient in our cohort with an HBV-DNA level ≥ 105 IU/mL who received HBIg and LAM did not experience HBV recurrence. This contrasts with results from earlier reports1,34,35 but is similar those described in recent studies.24,28,29,36 Hence, the presence of viral replication should not be considered an absolute contraindication for liver transplantation if an adequate postoperative prophylaxis is used.28,29

  • HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration

    2007, Journal of Hepatology
    Citation Excerpt :

    Hepatitis B recurrence was frequent in absence of hepatitis B reinfection prophylaxis after liver transplantation (OLT), resulting in considerably reduced graft and patient survival [1,2]. Reinfection rates dropped and survival improved significantly with the use of hepatitis B immunoglobulin (HBIG) prophylaxis [3–19]. High viral replication at time of transplantation was shown to be the key risk factor for reinfections in patients receiving HBIG mono-prophylaxis [7,12,20,21].

View all citing articles on Scopus
View full text